CVS Health opens digital innovation lab

CVS Health has officially opened its Digital Innovation Lab in Boston, a facility focused on developing digital services and personalized capabilities that offer an accessible and integrated personal pharmacy and health experience. The lab will serve as a hub for the rapidly growing digital team at CVS Health, which will remain headquartered in Woonsocket, R.I.

"At CVS Health, everything we do is to help people on their path to better health, and digital technologies are an amazingly effective way to achieve this," said Brian Tilzer, senior vice president and chief digital officer for CVS Health, in a release. "Digital technologies are ubiquitous and highly configurable--a powerful combination, because it allows us to empower our customers anytime and anywhere. That's why we are doubling our digital investment, anticipating our customers' increasing preference to manage their health digitally. The opening of this Innovation Lab is a significant step forward on this path."

The Digital Innovation Lab will help with the CVS Health digital team's mission to run like a startup, accelerating speed-to-market and impact of digital innovation across the enterprise, by using the resources of the lab to rapidly test, improve and implement new programs.

Primary focuses of the lab will include the exploration of breakthroughs for digital health through innovation in mobile, personalization, multi-channel e-commerce, connected health and digital therapeutics. CVS Health will further its pace and breadth of innovation through partnerships with promising startups and mature companies alike in the digital and healthcare space.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.